Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. – Trademark Portfolio
Entity Type: 16
Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 31 (Natural Agricultural Products) across 2 Nice Classification classes. Currently, 0 trademarks are registered and 2 are pending. The owner is based in Guangzhou, Guangdong.
Shunxiang Road, Huadu District, Huadong Town
Building 2 (West Side), Floors 1-3, No.15-4, (Airport Huadu)
Guangzhou, Guangdong 510000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Raw and unprocessed agricultural, aquacultural, horticultural and forestry products
Frequently Asked Questions
How many trademarks does Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. have?
Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. has 3 U.S. trademarks filed with the USPTO. Of these, 2 pending, 1 abandoned.
What trademark classes does Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. file in?
Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 31 (Natural Agricultural Products). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What is Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd.'s trademark registration success rate?
Guangzhou Kangmaigu Pharmaceutical Technology Co., Ltd. has a 0% trademark registration rate, with 0 out of 1 resolved applications resulting in successful registration. Currently, 2 applications are pending review.